Home›Trial›NCT07311850
NCT07311850Phase 3RECRUITING

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Study Summary

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

Conditions
Obesity and Overweight
Interventions / Drugs
MET097Placebo
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F33/100
Study Details
Enrollment3500 participants
Primary Completion—
Lead SponsorMetsera, a wholly owned subsidiary of Pfizer
Data Retrieved2026-04-11 02:55:53.190390+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 3,500 participants
Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company F (33/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.